rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Birchtech Corp.

BCHT · NYSE American

Health CareLife-science toolsNot moving yet

BCHT stood above a rising 150-day average in 15 of the last 52 weekly readings, and has been out of that trend for the last 37 weeks. It is 28.1% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 37
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$1.5M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
27 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 15 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.4MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Richard MacphersonPresident and CEObought312,500at $2.4027 Feb 2026filed 2 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders27+5 on the quarter
New · exited9 · 4
Reported value$9.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
HEARTLAND ADVISORS INCunchanged · filed 11 Aug 20261,000,000$2.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 2026721,182$1.5M+721,182
Ancora Advisors LLCadded · filed 14 Aug 2026700,244$1.4M+271,558+63.3%
CHAPIN DAVIS, INC.unchanged · filed 7 Jul 2026686,693$1.4M00.0%
Aristides Capital LLCunchanged · filed 13 Aug 2026425,000$871K00.0%
WHITE PINE CAPITAL LLCadded · filed 5 Aug 2026330,154$677K+40,981+14.2%
GEODE CAPITAL MANAGEMENT, LLCnew · filed 12 Aug 2026139,192$285K+139,192
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 2026103,667$213K+103,667
BlackRock, Inc.new · filed 7 Aug 202671,250$146K+71,250
ARS Investment Partners, LLCadded · filed 9 Jul 202664,200$132K+13,100+25.6%
31 Dec 2025 – 30 Jun 2026
31526Dec 25Mar 26Jun 26

Everyone who traded it

Richard MacPherson Company insiderPresident and CEO · last 27 Feb 20262 · 22
David M. Kaye Company insiderDirector · last 12 Dec 20250 · 0
John Pavlish Company insiderSenior VP/Chief Tech Officer · last 11 Dec 20250 · 0
Mitzi H. Coogler Company insiderDirector · last 9 Jan 20250 · 0
Christopher Greenberg Company insiderChairman of the Board · last 15 Jan 20243 · 0
Fiona Fitzmaurice Company insiderChief Financial Officer · last 15 Jan 20240 · 0
James Trettel Company insiderVice President of Operations · last 15 Jan 20240 · 0
Troy J. Grant Company insiderDirector · last 15 Jan 20240 · 0
Alterna Core Capital Assets Fund Ii, L.p. Company insider10% owner · last 28 Oct 20220 · 0
Jami L. Satterthwaite Company insiderChief Financial Officer · last 31 May 20220 · 0
Richard H. Gross Company insiderVP and Chief Financial Officer · last 28 Jun 20190 · 0
Allan T. Grantham Company insiderOther · last 4 Jun 20191 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202542.0%
Operating profit marginFY 2025 · to 31 Dec 2025-17.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-4.1%
Research spendFY 2025 · to 31 Dec 202510.2%
Share count trendFY 2025 · to 31 Mar 202635.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.2M
Free cash flowFY 2025 · to 31 Dec 2025−$729K

Analyst forecasts

No analyst forecasts yet.